

ONE HUNDRED FOURTEENTH CONGRESS  
**Congress of the United States**  
**House of Representatives**

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING  
WASHINGTON, DC 20515-6115

Majority (202) 225-2927  
Minority (202) 225-3641

September 1, 2015

Dr. Dan Sosin  
Deputy Director  
Office of Public Health Preparedness and Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329

Dear Dr. Sosin:

Thank you for appearing before the Subcommittee on Oversight and Investigations on Tuesday, July 28, 2015, to testify at the hearing entitled "Continuing Concerns with the Federal Select Agent Program: Department of Defense Shipments of Live Anthrax."


Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

Also attached are Member requests made during the hearing. The format of your responses to these requests should follow the same format as your responses to the additional questions for the record.

To facilitate the printing of the hearing record, please respond to these questions and requests with a transmittal letter by the close of business on September 15, 2015. Your responses should be mailed to Jessica Wilkerson, Oversight Associate, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, D.C. 20515 and e-mailed in Word format to [jessica.wilkerson@mail.house.gov](mailto:jessica.wilkerson@mail.house.gov).

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,



Tim Murphy  
Chairman

Subcommittee on Oversight and Investigations

cc: Diana DeGette, Ranking Member, Subcommittee on Oversight and Investigations

Attachments

Attachment 1—Additional Questions for the Record

The Honorable Frank Pallone, Jr.

1. DoD completed a review of the inadvertent anthrax shipments and found that procedures to irradiate and kill anthrax spores may be ineffective. The review determined that there is a lack of standardized procedures across DoD labs, and there may be insufficient scientific information on how best to irradiate anthrax.
  - a. What is CDC doing to ensure that inactivation procedures across the Federal Select Agent Program are effective?
  - b. Is the agency considering additional rule making or other guidance to ensure that labs are using scientifically validated methods of inactivating dangerous pathogens and toxins?
2. In the past year, the Centers for Disease Control and Prevention (CDC) reported a number of incidents in its high-containment laboratories.
  - a. What steps has the CDC taken in the past year to address the incidents involving CDC's laboratories and prevent them from recurring?
3. The July 28, 2015, hearing focused both on the Department of Defense's (DoD) inadvertent shipments of live anthrax from Dugway Proving Ground over a period of more than 10 years and incidents at CDC's laboratories in the past year or so.
  - a. Are these two situations related, and if so, how?
4. In July 2015, CDC Director Tom Frieden announced a comprehensive review of how the CDC regulates laboratory safety and security, nationwide. Dr. Frieden noted that the report will be managed by the director of the Office of Public Health Preparedness and Response.
  - a. What motivated CDC to conduct this comprehensive review?
  - b. How is this new review different from last year's examination of CDC lab safety?
  - c. Will there be overlap between the two reports?

## Attachment 2—Member Requests for the Record

*During the hearing, Members asked you to provide additional information for the record, and you indicated that you would provide that information. For your convenience, descriptions of the requested information are provided below.*

### The Honorable Tim Murphy

Please provide the policy memo referenced in the USA Today article regarding CDC's requirement that reports be sent to the top lab safety office.

### The Honorable Diana DeGette

1. Please describe to the Committee steps that CDC may take to increase the culture of safety at the labs that are part of the Federal Select Agent Program.
2. Please provide additional detail as to why the CDC believes that the problems discussed in this hearing took place at one specific lab, the Dugway Proving Ground.

### The Honorable Michael C. Burgess

1. Please provide to the Committee the materials that the CDC provided to the emergency rooms around the breach area.
2. What was the geographic radius used to determine which emergency rooms should receive those materials?

### The Honorable Paul Tonko

1. How many times has a lab lost its registration?
2. Please provide details on the specific enforcement actions that the CDC has taken against labs that have violated the Federal Select Agent Program.

### The Honorable Susan Brooks

Please provide a detailed explanation of how the process for death certificates work, including what information is required to be included in the certificate.

### The Honorable Richard Hudson

Please provide additional detail on the practice of sending death certificates with inactivated materials. In particular, why was the death certificate sent with the "blind sample" test not provided until much later?